Company Profile · Healthcare

Medpace Holdings Inc

MEDP · US
Industry
Pharma Outsourcing (CRO)
Exchange
US
Country
USA
IPO date
Aug 11, 2016
Employees
6,300
Website
www.medpace.com
Current Price
$460.2
Live · Jun 18, 2026
Fair Buy
≤ $380
Margin-of-safety entry
Baillie Growth Score
49/100
Weak
Intrinsic Value · Three-Tier Range Current price $460.2 Live · Between the fair and optimistic ranges

Composite valuation range · conservative $290–$360 / fair $380–$460 / optimistic $520–$600. At $460.2, Between the fair and optimistic ranges.

At publication $454.25 (Jun 6, 2026)

Research on this stock
Medpace Holdings
MEDP · US
Watch
Medpace Holdings Zen Horizon Framework Deep-Dive Research

Medpace Holdings is one of the leading U.S. full-service clinical CROs, focused on small and mid-sized biotech clients, founder-controlled, debt-free, and an exceptional high-ROIC compounder. The core thesis is that business quality remains outstanding, but current valuation, weakening leading indicators, and biotech funding-cycle exposure leave little margin of safety. Research rating Watch: a high-quality compounder worth monitoring, with a better entry point likely below $380 or after book-to-bill recovers above 1.0x.

Pharma Outsourcing (CRO) Baillie 49 Jun 6, 2026
About the company

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Financial snapshot
Market cap$13.14B
Revenue (TTM)$2.68B
EBITDA$591.01M
Profit margin17.19%
ROE77.25%
P/E (TTM)28.97
Forward P/E27.47
PEG2.84
EPS$15.88
52-week range$301.90 – $628.92
Analyst target$442.83
Analyst rating3.3 / 5

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

Background

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.